EveliQure Biotechnologies GmbH

Founded

2012

Staff

7

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

human health

Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries.

R&D:Eveliqure has developed a novel vaccine technology platform based on a live attenuated vaccine strain of the bacterium Shigella, engineered to induce broad protection against infection caused by different species and serotypes. Eveliqure has also introduced the expression of non-shigella derived antigens into the strain to achieve protection against multiple pathogens. ShigETEC, is the first-generation vaccine candidate that targets Shigella and ETEC, two of the major pathogens causing diarrhea.